| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Regeneration Technologies, Inc. |
| One Innovation Drive, Alachua, FL 32615 * (904) 418-8888 |
| Business Description | The company is a leader in the use of biologics and tissue-based innovations that are used to repair and promote the natural healing of human bone and other human tissues. |
| Offering Information Company has | |||
| Trading As | RTIX (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 4/27/00 |
| Domestic Shares Offered | 5,700,000 | Offer Date | 8/9/00 |
| Foreign Shares Offered | 0 | Filing Range | $12.00 - $14.00 |
| Company Shares | 5,700,000 | Offer Price | $14.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $0.980 |
| Gross Proceeds | $79,800,000 | Selling | $0.550 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 21,310,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Banc of America Securities LLC | Lead Manager | (415) 627-2100 |
| Lehman Brothers Incorporated | Co-manager | (212) 526-8100 |
| Stephens Inc. | Co-manager | (501) 377-2130 |
| Warburg Dillon Read LLC | Co-manager | (203) 719-3000 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/98 | 12/31/99 | |||||
| Revenues | - | - | - | 35.257 | 72.020 | - | - |
| Income from Oper. | - | - | - | -4.176 | 2.439 | - | - |
| Net Income | - | - | - | -4.142 | 2.959 | - | - |
| E.P.S | - | - | - | - | - | - | - |
| Revenue Growth (%) | - | - | - | 104.271 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | 3.39 | - | - |
| Net Profit Margin (%) | - | - | - | - | 4.11 | - | - |
| Cash Flow - Oper. | -6.48 | - | - | ||||
| Cash Flow - Inv. | -2.87 | - | - | ||||
| Cash Flow - Fin. | 12.95 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 48.54 | Current Assets | 41.20 | Current Ratio | 1.52 |
| Total Liab. | 33.10 | Current Liab. | 27.15 | Debt Ratio | 68.20% |
| Total Equity | 15.44 | Working Cap. | 14.05 | Debt to Equity Ratio | 2.14 |
| Cash | 7.54 | Return on Assets | 6.10% | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used to fund continued research and development, to construct and equip a new manufacturing facility, to construct additional BioClense systems and other automated processing systems, to expand tissue recovery and distribution activities and for general corporate purposes including working capital. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Fulbright & Jaworski |
| Bank's Law Firm | Mintz, Levin, Cohn, Ferris, Glovsky And Popeo |
| Auditor | Deloitte & Touche |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| The University of Florida Tissue Bank, Inc. | 16.30 | |
| The University of Florida Research Foundation | 16.30 | |
| LB I Group Inc | 8.30 | |
| Euro-America-II, L.P. | 5.30 | |
| Stephens-Regeneration LLC | 5.00 | |
| Medtronic Asset Mgt., Inc. | 5.00 | |
| RTI Advisory Group LLC | 4.60 | |
| Note: represents ownership of 5% or more prior to the offering. | ||